Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
ICAD INC (ICAD) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/05/2021 GN iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition
03/15/2021 GN iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography
03/08/2021 GN New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting
03/03/2021 GN iCAD to Participate in the Cowen 41st Annual Health Care Conference
03/03/2021 GN iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock
02/18/2021 GN iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24
01/19/2021 GN iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference
01/06/2021 GN iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
12/29/2020 GN iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
12/10/2020 GN Solis Mammography Adopts iCAD's ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution
12/03/2020 GN iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution
11/30/2020 GN iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020
11/25/2020 GN iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress
11/24/2020 GN iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales
10/23/2020 GN New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
10/20/2020 GN iCAD Signs Distribution Agreement with Change Healthcare
09/20/2020 GN iCAD Responds to CMS' Finalized Radiation Oncology Alternative Payment Model
09/18/2020 GN iCAD's IORT Excluded from CMS's Radiation Oncology Alternative Payment Model
08/27/2020 GN iCAD to Present at the LD Micro 500 Virtual Conference
08/10/2020 GN iCAD to Participate in the Guggenheim MedTech Disruptors Summit
08/04/2020 GN iCAD Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020
07/15/2020 GN ProFound AI™ Risk Receives CE Mark in Europe
06/29/2020 GN iCAD Added to Russell 2000® Index
04/23/2020 GN iCAD Announces Pricing of $12.5 Million Registered Direct Offering
04/13/2020 GN iCAD Partners with the TME Breast Care Network to Host Virtual Event: Breast Care Roundtable in the Age of COVID-19
02/27/2020 GN iCAD Reports Fourth Quarter and Full-Year 2019 Financial Results
12/04/2019 GN iCAD's ProFound AI Joins Nuance AI Marketplace for Diagnostic Imaging
12/02/2019 GN iCAD to Showcase Leading Breast Health Solutions Suite Including Expanded ProFound AI™ Platform at RSNA Annual Meeting
11/26/2019 GN iCAD to Participate at the Piper Healthcare Conference
11/18/2019 GN iCAD to Participate at the Cannacord Genuity Medtech & Diagnostics Forum
10/30/2019 GN iCAD Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2019
10/01/2019 GN iCAD Showcases ProFound AI™ Platform at European Society of Breast Imaging Annual Scientific Meeting in Budapest
09/16/2019 GN iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer
09/10/2019 GN iCAD's ProFound AI Reader Study Published in Radiology: Artificial Intelligence
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy